BORDSFORD Project
BOaRD expert Screening FOR Dysimmunity

Many patients with neuropsychiatric disorders have positive inflammatory markers but with impossibility of highlighting a specific pathologic auto-antibody, making current techniques insufficient to respond to clinicians.

A subgroup of patients with pharmacoresistant unexplained neuropsychiatric symptoms, could benefit from the detection of auto antibodies and adapted immunomodulatory therapy where appropriate.

BORDSFORD meets the goal to set a functional platform called ImmunOptiC in order to detect the presence of autoantibodies and in the same time measure their pathogenicity.

We build a translational project with a board expert of clinicians and searchers to explore the relevance of dysimmunity diagnosis in medical care. We plan to respond to the urgent technological and clinical need by setting a unique multiscale analysis platform in order to provide clinicians a robust, high-sensitivity, and functional outcome about autoantibodies.

Our collective effort gather experts from clinical services and from fundamental research labs, building a unique platform for detection with clinical expertise.

In terms of public health, the optimization, through fundamental research, of a reliable, reproducible technique that can be applied to large populations, represents an indispensable preliminary work for the harmonization of international techniques worldwide for the detection of autoimmunity.

SPARK VALUE: We hope to gain vital translational research know-how from experienced SPARK mentors, broaden our networks and expand them internationally, and learn from our peer SPARKees and similar projects from earlier patches. SPARK is a unique opportunity to develop our link with industries to enter in the competitive landscape of the medical diagnosis.